CSIMarket
 
Merus N v   (NASDAQ: MRUS)
Other Ticker:  
 
 
Price: $45.0100 $0.56 1.260%
Day's High: $45.685 Week Perf: -4.72 %
Day's Low: $ 44.41 30 Day Perf: -1.14 %
Volume (M): 85 52 Wk High: $ 61.61
Volume (M$): $ 3,839 52 Wk Avg: $48.20
Open: $44.63 52 Wk Low: $37.77



 Market Capitalization (Millions $) 2,893
 Shares Outstanding (Millions) 64
 Employees 71
 Revenues (TTM) (Millions $) 36
 Net Income (TTM) (Millions $) -215
 Cash Flow (TTM) (Millions $) 89
 Capital Exp. (TTM) (Millions $) 2

Merus N V
Merus N is a company that specializes in creating high-quality products for use in the health and wellness industry. They are known for their innovative and unique approach to developing effective solutions for various health concerns.

Merus N focuses on using natural ingredients and advanced scientific research to create their products. They prioritize safety and efficacy, ensuring that their customers receive the best possible results.

Their product range includes dietary supplements, skincare products, and personal care items. These products are formulated to address specific health issues such as immune support, digestive health, stress management, and anti-aging.

Merus N emphasizes the use of sustainable and environmentally friendly practices in their manufacturing processes. They are dedicated to creating products that are both beneficial for consumers and respectful of the planet.

Overall, Merus N is committed to providing high-quality health and wellness solutions that enhance people's lives and promote overall well-being.


   Company Address: Uppsalalaan 17 Utrecht 3584
   Company Phone Number: 253 8800   Stock Exchange / Ticker: NASDAQ MRUS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -3.56%    
HCM   -11.84%    
KPTI   -21.01%    
RYTM        3.8% 
SUPN        0.03% 
XNCR   -17.05%    
• View Complete Report
   



Product Service News

Advancements in Oncology Merus Initiates Phase 2 Trial of Petosemtamab in Metastatic Colorectal Cancer

Published Sun, Dec 29 2024 5:57 PM UTC

The landscape of oncology is continually evolving, propelled by innovative therapies and clinical trials aimed at addressing hard-to-treat conditions. In a noteworthy development, Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, has initiated a Phase 2 trial of its promising monoclonal antibody, petosemtamab, for patients with heavily pretreated metastatic color...

Product Service News

Unlocking Wealth The Heirs Rights Property Report and Its Implications for Indianas Future

Published Tue, Dec 17 2024 4:41 PM UTC

In a significant collaboration aimed at addressing the complexities of property transfers and ownership rights, the Federal Home Loan Bank of Indianapolis (FHLBI) and Black Onyx Management recently released the Heirs Rights Property Report, focusing on major counties throughout Indiana. This report brings to light the often-overlooked implications of property rights when it ...

Clinical Study

Merus N.V.s Petosemtamab Shows Promise in Head and Neck Cancer Treatment

Published Sat, Dec 7 2024 6:30 AM UTC

Merus N.V., a clinical-stage immuno-oncology company, has released interim data showcasing the efficacy of its novel antibody, Petosemtamab, in second-line or later (2L+) recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). This data indicates clinically meaningful activity in this challenging-to-treat cancer population. Concurrently, the company reported...

Product Service News

Merus Breaks New Ground with FDA Approval of BIZENGRI A Beacon of Hope for Patients with NRG1+ Cancers

Published Wed, Dec 4 2024 9:55 PM UTC

In a significant milestone for cancer treatment, Merus N.V. has received the U.S. Food and Drug Administration (FDA) approval for BIZENGRI (zenocutuzumab-zbco), marking a breakthrough in the fight against advanced pancreatic adenocarcinoma and nonsmall cell lung cancer (NSCLC) associated with a neuregulin 1 (NRG1) gene fusion. This pioneering therapy is now the first and onl...

Clinical Study

Merus Doses First Patient in Phase 3 Trials for Petosemtamab in Oncology Indications

Published Mon, Sep 30 2024 12:00 PM UTC

Merus N.V., a clinical-stage oncology company specializing in the development of innovative multispecific antibodies, has announced significant advancements in its clinical trials for petosemtamab, a novel therapy targeting epidermal growth factor receptor (EGFR) and LGR5. The company has recently initiated two pivotal clinical trials, expanding its exploration of petosemtam...







Merus N V's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com